Journal of Clinical Oncology
Articles in this Issue
Combining the albumin-bilirubin (ALBI) score and ECOG performance status for enhanced prognostication in advanced biliary tract cancer treated with durvalumab-based immunochemotherapy.
485 Background: The Eastern Cooperative Oncology Group performance status (ECOG PS) is fundamental for prognostication in...
Extracellular vesicle tissue factor and venous thromboembolism outcomes in pancreatic cancer patients: A systematic review.
780 Background: Pancreatic cancer has the highest risk of venous thromboembolism (VTE) among all cancers, with incidence r...
Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: A network meta-analysis of randomized controlled trials.
170 Background: Colorectal cancer (CRC) remains a leading cause of cancer mortality, with limited survival in advanced dis...
The effect of adjuvant chemotherapy on prognosis in patients with familial pancreatic cancer.
691 Background: Being familial pancreatic cancer (FPC) is defined as a family in which at least two first-degree relatives...
<i>ERBB3</i> driver genomic alterations in intrahepatic cholangiocarcinoma: A genomic landscape and clinical outcome study.
597 Background: HER3, a tyrosine kinase receptor encoded by ERBB3 lacks intrinsic...
Five decades of esophageal cancer mortality in the United States: Shifting patterns by sex, race, age, and income.
301 Background: Esophageal cancer is the sixth leading cause of cancer-related death worldwide and continues to be a major...
Real-world survival and responses to HER2 directed treatment in gastrointestinal cancers based on HER2 non-amplified mutation and HER2 amplification/overexpression status.
307 Background: Human epidermal growth factor receptor 2 (HER2) plays a vital role in cell proliferation, apoptosis, and u...
Characterization of piwi-RNA signatures in colorectal cancer.
227 Background: Although incidence and mortality rates have declined, colorectal cancer (CRC) remains a leading cause of c...
Inferring optimal detection of <i>MTAP</i> homozygous loss (homozygous deletion) in gastric cancer: Associations with treatment exposure, disease site, and clinical outcomes.
327 Background: Validated homozygous loss detection is becoming increasingly important in clinical practice, with...
Glucagon-like peptide 1 receptor agonists: More than just weight loss medications.
520 Background: Emerging evidence suggest a protective effect for Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RA) wit...
Short-course radiotherapy (SCRT) followed by immunochemotherapy plus fruquintinib as the total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT).
128 Background: The phase III trial (UNION) evaluating SCRT followed by immunochemotherapy in patients (pts) with LARC has...
Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma.
755 Background: Glufosfamide couples a glucose moiety to an ifosfamide mustard to exploit tumor glucose transport and deli...
Role of liquid biopsy in diagnosis, prognosis, and monitoring of hepatocellular carcinoma: A systematic review.
480 Background: Hepatocellular carcinoma (HCC) remains a major global health burden, primarily driven by risk factors such...
SYLT-030: Efficacy and safety of tislelizumab plus mFOLFOX6 versus tislelizumab plus POF (paclitaxel + mFOLFOX6) as first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): A multicenter, open-label, randomized phase III trial.
TPS463 Background: Tislelizumab is an anti-PD-1 antibody. The addition of tislelizumab to a doublet chemotherapy regimen w...
Immune related adverse events (irAEs) in Lynch vs non-Lynch microsatellite instability-high (MSI-high) gastrointestinal (GI) cancers: A retrospective cohort study.
830 Background: Immune checkpoint inhibitors (ICIs) are standard therapy for MSI-H GI cancers. Lynch syndrome, caused by g...
Prognostic value of regional lymph node ratio (LNR) in locally advanced gastric cancer: A single center analysis.
448 Background: Objective: to evaluate the relationship between the ratio of metastatic regional lymph nodes (LN) in local...
Validation of CanCatch Surf assay for tissue-agnostic detection of minimal residual disease in colorectal cancer.
21 Background: Monitoring molecular residual disease (MRD) status showed prognostic value for recurrence prediction in col...
Clinical and economic implications of venous thromboembolism in pancreatic cancer patients: Evidence from the National Inpatient Sample.
667 Background: Venous thromboembolism (VTE) remains one of the most devastating complications of pancreatic cancer, often...
A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma.
368 Background: Co-inhibition of lymphocyte activation gene-3 (LAG-3) and programmed cell death protein-1 (PD-1) may enhan...
Procedure-specific mortality risk in octogenarians undergoing curative GI cancer resection: A contemporary U.S. analysis.
737 Background: Octogenarians increasingly undergo curative GI cancer surgery, yet most risk tools apply a uniform “age pe...
Real-world outcomes of locally advanced mismatch repair deficient colorectal tumours treated with immune checkpoint inhibitors.
75 Background: Immunohistochemical analysis of mismatch repair deficient (dMMR) status in colorectal (CRC) cancers is stan...
Impact of metabolic and lifestyle risk factors on hepatocellular carcinoma incidence and outcomes.
524 Background: Hepatocellular carcinoma (HCC) arises from a spectrum of underlying liver conditions and metabolic risk fa...
Post-hoc central radiological review of the ALTAIR study in patients with molecular residual disease (MRD) following curative resection of colorectal cancer (CRC).
138 Background: Tumor-informed circulating tumor DNA (ctDNA) testing is recognized as a powerful predictor of CRC recurren...
Proximal gastrectomy versus total gastrectomy in locally advanced upper gastric cancer after neoadjuvant chemotherapy combined with tislelizumab: The preliminary results of a multicenter, prospective, randomized, phase 3 clinical trial.
406 Background: Emerging evidence suggests that the preservation of certain lymph nodes adjacent to tumors can enhance the...
Artificial intelligence approach to estimating trial feasibility with OncoLLM.
822 Background: Assessing trial feasibility and predicting accrual is difficult and often inaccurate, resulting in the cos...